21 October 2025 : Original article
Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections
Nam Ho
ABDEF 1, Thu Thi Nguyen BCDF 1, Nam Van Do BCD 1, Chi Tam Nguyen BEF 1, Su Xuan Hoang DEF 2, Khanh Vo Ngoc Hoang BEF 3, Trung Dinh Ngo ABDEF 1*
DOI: 10.12659/AOT.949942
Ann Transplant 2025; 30:e949942
Table 5 Infection comparison between the low-dose r-ATG and Basiliximab groups.
| Total (n=150) | Low-doser-ATG (n=37) | Basiliximab (n=113) | P value | |
|---|---|---|---|---|
| CMV viremia | 20 (13.33) | 4 (10.81) | 16 (14.15) | 0.783 |
| BK viremia | 24 (16) | 5 (13.51) | 19 (16.81) | 0.798 |
| Bacterial infection (%) | 9 (6) | 2 (5.41) | 7 (6.19) | 1 |
| Viral pneumonia (%) | 0 | 0 | 0 | 0 |
| Fungal (%) | 4 (2.67) | 1 (2.70) | 3 (2.65) | 1 |
| Tuberculosis (%) | 0 | 0 | 0 | 0 |
| r-ATG – rabbit anti-thymocyte globulin; CMV – cytomegalovirus; BK – polyomavirus BK. | ||||